| Prev Close | 0.27 |
| Day Low/High | 0.26 / 0.28 |
| 52 Wk Low/High | 0.17 / 2.79 |
| Avg Volume | 1.37M |
| Exchange | AMEX |
| Shares Outstanding | 41.93M |
| Market Cap | 11.33M |
| EPS | -1.20 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Completes Important First Step toward Production of Unlimited Killer T Cells Designed to Attack Cancer Cells
Live presentation will take place on December 7, 2017 at 9:30 a.m. PT (12:30 p.m. ET)
The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of ImmunoCellular Therapeutics, Ltd.
The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of ImmunoCellular Therapeutics, Ltd.
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in ImmunoCellular Therapeutics, Ltd.
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who purchased ImmunoCellular...
The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of ImmunoCellular Therapeutics, Ltd.
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in ImmunoCellular Therapeutics, Ltd.
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who purchased ImmunoCellular...
Rosen Law Firm, a global investor rights law firm, reminds purchasers of ImmunoCellular Therapeutics, Ltd.
The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of ImmunoCellular Therapeutics, Ltd.
Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against ImmunoCellular Therapeutics, Ltd.
Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against ImmunoCellular Therapeutics, Ltd.
Khang & Khang LLP (the "Firm") announces the filing of a class action lawsuit against ImmunoCellular Therapeutics, Ltd.
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of ImmunoCellular Therapeutics, Ltd.
An SEC enforcement action uncovers the deep involvement and brazen misbehavior of biotech CEOs in an illegal stock promotion scheme.
TheStreet's biotech columnist offers his own report card on biotech stocks.
A defrocked analyst brushes off the serious problems weighing on Northwest Bio. Instead, he jacks the tired 'blame the shorts' excuse to another level.
These stocks look ready to break out and trade higher from current levels.
These under-$10 stocks are within range of triggering breakout trades.
Lion Bio received an SEC subpoena related to the Galena DreamTeam investigation.
These under-$10 stocks look ready to trade higher from current levels.
Investors in ImmunoCellular Therapeutics Ltd saw new options begin trading this week, for the April 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the IMUC options chain for the new April 19th contracts and identified the following call contract of particular interest.
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Twelve weeks have passed since Northwest Bio said an interim analysis of the DCVax phase III study was underway. Where are the results?
These under-$10 stocks look ready to trade higher from current levels.
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) announced today that the first patient in the phase I clinical trial of ICT-121, a cancer vaccine targeting recurrent glioblastoma multiforme ...
